The Rise of GLP-1 Analogues: Navigating RDC 96/2008 and Technical Note 200/2025 in Brazil
The rise of GLP-1 analogues, such as Semaglutide and Tirzepatide, has revolutionized the treatment of obesity and metabolic diseases. However, the global popularity of these therapies has brought significant regulatory challenges in Brazil. Pharmaceutical industries, distributors, and pharmacies must maintain rigorous compliance with ANVISA standards to ensure operational safety.
Pharmaceutical Advertising: The Boundaries of RDC 96/2008
Communication in the Brazilian pharmaceutical sector follows a fundamental premise: medications are not consumer goods; they are essential public health assets. RDC No. 96/2008 (a specific Board Resolution) sets strict limits to ensure that drug marketing respects safety and ethical standards.
- Restricted to Lay Audiences: Prescription-only medicines (POM), such as "weight-loss pens," cannot be advertised directly to consumers (DTC Advertising). In Brazil, unlike in the US, all communication must be technical and directed exclusively to licensed healthcare professionals (doctors and pharmacists).
- Ban on Aesthetic Promises: The use of "before and after" images or promises of guaranteed results is strictly prohibited. Such practices are seen as inducing indiscriminate use and violating sanitary ethics.
Technical Note 200/2025: Rigor in Biotech API Sourcing
The recent publication of Technical Note No. 200/2025 by ANVISA introduced a new level of scrutiny over the import and compounding of Active Pharmaceutical Ingredients (APIs)—specifically biotechnological ones used for GLP-1 analogues. The goal is to prevent the sale of products without proven equivalence, ensuring the safety and efficacy of treatments.
International and local companies must focus on two critical points:
- Manufacturer Qualification (Homologation): The import of biotech APIs is only authorized if the manufacturer is the exact one already registered and audited by ANVISA in Brazil. Essentially, the importer must hold the specific product registration associated with that manufacturer.
- National Quality Control: For pharmacies and authorized establishments, compounding requires quality control tests performed on Brazilian soil to ensure the purity and stability of sterile preparations.
The Risk of Use Without Clinical Indication
The off-label use of Tirzepatide (Mounjaro) and other GLP-1 analogues for aesthetic purposes without medical supervision poses a high risk to public health and the legal security of companies. The pharmacotechnical complexity of these drugs requires them to be used strictly within ANVISA-approved clinical protocols to avoid serious adverse events.
Conclusion: Compliance as a Competitive Advantage
In Brazil’s highly scrutinized and competitive healthcare market, regulatory compliance is not an obstacle—it is the ultimate safeguard for brand reputation. Staying aligned with ANVISA standards and sanitary safety guidelines is essential for long-term operational viability.
At Stone Okamont, we assist our partners in validating strategies and auditing regulatory processes, ensuring that technological innovation is always accompanied by legal certainty.